Myeloma Center

You are here

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.

TitleCarfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.
Publication TypeJournal Article
Year of Publication2017
AuthorsLudwig H, Dimopoulos MA, Moreau P, Chng W-J, Goldschmidt H, Hajek R, Facon T, Pour L, Niesvizky R, Oriol A, RosiƱol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Palumbo A, Gillenwater HH, Mohamed N, Aggarwal S, Feng S, Joshua D
JournalLeuk Lymphoma
Volume58
Issue10
Pagination2501-2504
Date Published2017 Oct
ISSN1029-2403
DOI10.1080/10428194.2017.1298755
Alternate JournalLeuk. Lymphoma
PubMed ID28306371